Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Oden6570on Apr 07, 2022 6:37am
394 Views
Post# 34583207

TD -Study II has delivered significant clinical results

TD -Study II has delivered significant clinical results

Theralase Provides Update on Phase II Bladder Cancer Clinical Study -- Says "On Track" to Achieving Study Objectives

08:35 AM EDT, 04/05/2022 (MT Newswires) -- Theralase Technologies (TLT.V), a clinical-stage pharmaceutical company, on Tuesday provided an update on the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Study (Study II).

Theralase successfully completed a Phase Ib NMIBC Clinical Study (Study I), which enrolled and provided the primary study treatment, at the therapeutic dose, for three patients. To date, Study II has enrolled and provided the primary study treatment for 35 patients, which when combined with the Study I data, leads to a total of 38 patients, who have received at a minimum, the primary study treatment.

Study II has delivered significant clinical results to date for the primary, secondary and tertiary objectives, Theralase said:

From the 38 patients treated to date in Study II, those evaluable patients, have achieved 50.0% CR (complete response) at 90 days and 25.0% have maintained this CR for at least 450 days, since primary study treatment. Additionally, total responders (CR +Partial Response, PR) at 90 days is 60.5% and 18.4% at 450 days. There is significant data still pending.

Theralase also noted that only seven serious adverse events (SAEs) were reported to date, and the company believes these are unrelated to the study drug or study device.

"In conclusion, it is encouraging to see, from the preliminary clinical data that the company has accumulated to date, that if the trends continue, then Theralase is on track to achieving the primary, secondary and tertiary Study II objectives," Dr. Vera Madzarevic, Director of Clinical Development and Quality Assurance, said.


<< Previous
Bullboard Posts
Next >>